Gamida Cell GMA shares are trading higher Wednesday after the company reported the results of the efficacy and safety for its Phase 3 study of Omidubicel at the TCT meetings of ASTCT and CIBMTR.
Gamida Cell Ltd is a biopharmaceutical company involved in developing advanced cell therapies with the potential to cure cancer and rare, serious hematologic diseases. The company's product includes NiCord that is a cell therapy based on NAM-expanded cord blood designed to enhance and expand the life-saving benefits of hematopoietic stem cell transplant.
Gamida Cell stock was up 24.29% at $12.29. The stock has a 52-week high of $15 and a 52-week low of $2.60
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
